Atlas Trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Clinical trial NCT04718883 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04718883
Sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2021-01-13
Primary completion
2023-10-25
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.